Search Follow us
Refine By

Stock Exchange


Type of Publication


1 - 6 of 6
Sort by: popularity | newest
Page  of 1
ASLAN Pharmaceuticals

Termination of coverage

Termination | Pharmaceuticals & healthcare | 22 Nov 2018

Edison Investment Research is terminating coverage on ASLAN Pharmaceuticals (ASLN). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

ASLAN Pharmaceuticals

Enrolment for China study adjusted

Update | Pharmaceuticals & healthcare | 19 Sep 2018

ASLAN announced it would be amending the protocol for its ongoing Chinese pivotal trial of varlitinib in biliary tract cancer (BTC). The patients being enrolled in China had more severe disease than expected based on historical controls, which manifested as a weaker than expected response to treatment on the trial. Due to delays, the Chinese study may not complete before the ongoing TREETOP study, which would then serve as a pivotal study for approval in China and is expected to complete in 2019.

ASLAN Pharmaceuticals

ASLAN004 a go for atopic dermatitis

Update | Pharmaceuticals & healthcare | 09 Jul 2018

ASLAN announced in July 2018 that it has received clinical trial authorisation in Singapore to conduct a Phase I study of ASLAN004 for the treatment of atopic dermatitis (AD). The product is a monoclonal antibody targeting interleukin 13 receptor α 1 (IL13Rα1). The Phase I dosing study will consist of a single dose escalation in healthy volunteers and a multiple dose escalation in AD patients.

ASLAN Pharmaceuticals

Additional clinical support for varlitinib

Update | Pharmaceuticals & healthcare | 07 Jun 2018

ASLAN presented data at ASCO from a Phase Ib dosing study examining varlitinib in combination with carboplatin, paclitaxel and Herceptin. Patients were enrolled across a range of cancers, but the majority (20/37) were HER2+ metastatic breast cancer patients. The drug demonstrated efficacy across the study and the addition of Herceptin at the optimal dose did not induce toxicity, suggesting the potential of future combinations.

ASLAN Pharmaceuticals

ASLAN acquires full rights to varlitinib

Update | Pharmaceuticals & healthcare | 10 Jan 2018

In January 2018, ASLAN announced that it had fully acquired the global commercial rights to varlitinib from its partner, Array BioPharma. Previously, the agreement stipulated that ASLAN develop the drug and sublicense it, and we view the current agreement as a significant improvement. We believe that ASLAN brings significant value to the table in Asian development capacity. The licence is now consistent with the goal of directly commercialising varlitinib in the US and parts of Asia.

ASLAN Pharmaceuticals

Novel treatments for worldwide unmet needs

Initiation | Pharmaceuticals & healthcare | 07 Nov 2017

We are initiating coverage on ASLAN Pharmaceuticals, a clinical-stage drug developer focusing on in-licensing drugs with a high prevalence in Asia that are orphan indications in the West. The company's lead asset is the pan-HER inhibitor varlitinib, which is in clinical trials for biliary tract cancer (BTC, pivotal) and gastric cancer (GC, Phase II/III), both of which are widely prevalent in Asia. The company has also planned a Phase II trial of ASLAN003 targeting AML via the novel mechanism of inducing blast differentiation. We initiate at NT$9.5bn or NT$72.87 per share.